A. Azzedine
Impact in
- Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Gastroenterology top 10%
- Gastrointestinal Tumor Research and Treatment
Papers in
- Oncology 5
- Pancreatic and Hepatic Oncology Research 2
- Cancer Treatment and Pharmacology 2
- Colorectal Cancer Treatments and Studies 2
-
- Gastric Cancer Management and Outcomes 2
- Co-authors
- Olivier Bouché (6 shared papers)Laurent Bedenne (4 shared papers)Pascal Hammel (4 shared papers)Thomas Aparicio (4 shared papers)J Butel (2 shared papers)Noël Stremsdoerfer (2 shared papers)P. Rougier (2 shared papers)C. Mariette (2 shared papers)
In The Last Decade
A. Azzedine
8 papers receiving 994 citations
A. Azzedine's Hit Papers
Peers
Comparison fields: 5 of 50
- Oncology 670
- Gastroenterology 52
- Cancer Research 137
- Pulmonary and Respiratory Medicine 290
- Hematology 66
Countries citing papers authored by A. Azzedine
This map shows the geographic impact of A. Azzedine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Azzedine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Azzedine more than expected).
Fields of papers citing papers by A. Azzedine
This network shows the impact of papers produced by A. Azzedine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Azzedine. The network helps show where A. Azzedine may publish in the future.
Co-authors
The 25 scholars most cited alongside A. Azzedine, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study Hit paper breakdown → | 2008 | 530 |
| 2 | 2014 | 174 | |
| 3 | 2006 | 156 | |
| 4 | 2011 | 114 | |
| 5 | 2008 | 23 | |
| 6 | 2011 | 14 | |
| 7 | 2018 | 5 | |
| 8 | 2019 | 2 |
About A. Azzedine
A. Azzedine is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Dermatology and Epidemiology, having authored 8 papers that have together received 1.0k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (2 papers), Gastric Cancer Management and Outcomes (2 papers), Cancer Treatment and Pharmacology (2 papers), Colorectal Cancer Treatments and Studies (2 papers), Economic and Financial Impacts of Cancer (1 paper), Skin Diseases and Diabetes (1 paper), Multiple Myeloma Research and Treatments (1 paper) and Cancer therapeutics and mechanisms (1 paper). The work is most often cited by research in Oncology (670 citations), Gastroenterology (52 citations), Cancer Research (137 citations), Pulmonary and Respiratory Medicine (290 citations) and Hematology (66 citations). A. Azzedine has collaborated with scholars based in France and Belgium. Frequent co-authors include Olivier Bouché, Laurent Bedenne, Pascal Hammel, Thomas Aparicio, J Butel, Noël Stremsdoerfer, P. Rougier, C. Mariette, F. Mornex and Laurent Mineur. Their work appears in journals such as Journal of Clinical Oncology, The Lancet Oncology, Annals of Oncology, Gastric Cancer and Clinical and Experimental Dermatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.